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Abstract
Background: Brugada syndrome is an ion channelopathy that predisposes affected
subjects to ventricular tachycardia/fibrillation (VT/VF), potentially leading to sudden
cardiac death (SCD). Tpeak‐Tend intervals, (Tpeak‐Tend)/QT ratio and Tpeak‐Tend disper-
sion have been proposed for risk stratification, but their predictive values in Bru-
gada syndrome have been challenged recently.
Methods: A systematic review and meta‐analysis was conducted to examine their
values in predicting arrhythmic and mortality outcomes in Brugada Syndrome.
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PubMed and Embase databases were searched until 1 May 2018, identifying 29 and
57 studies.
Results: Nine studies involving 1740 subjects (mean age 45 years old, 80% male,
mean follow‐up duration was 68 ± 27 months) were included. The mean Tpeak‐Tend
interval was 98.9 ms (95% CI: 90.5‐107.2 ms) for patients with adverse events (ven-
tricular arrhythmias or SCD) compared to 87.7 ms (95% CI: 80.5‐94.9 ms) for those
without such events, with a mean difference of 11.9 ms (95% CI: 3.6‐20.2 ms,
P = 0.005; I2 = 86%). Higher (Tpeak‐Tend)/QT ratios (mean difference = 0.019, 95%
CI: 0.003‐0.036, P = 0.024; I2 = 74%) and Tpeak‐Tend dispersion (mean differ-
ence = 7.8 ms, 95% CI: 2.1‐13.4 ms, P = 0.007; I2 = 80%) were observed for the
event‐positive group.
Conclusion: Tpeak‐Tend interval, (Tpeak‐Tend)/QT ratio and Tpeak‐Tend dispersion were
higher in high‐risk than low‐risk Brugada subjects, and thus offer incremental value
for risk stratification.
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1 | INTRODUCTION
Brugada syndrome is a used to describe the combination of specific
ECG changes, the Brugada pattern, in addition to life threatening
arrhythmias and sudden cardiac death (SCD).1 Traditionally, it has
been considered a congenital ion channelopathy linked to abnormali-
ties in the cardiac sodium channel.2,3 Recently, pathogenic mutations
in other ion channels have been described. Mechanisms of arrhyth-
mogenesis can be broadly divided into triggered activity and re‐
entry. Of these, re‐entry is thought to be the predominant mecha-
nism underlying increased arrhythmogenicity in Brugada syndrome
requiring an increased spatial dispersion of repolarization. Such re‐
entrant activity may involve direct electrotonic activation during
phase 2 of the cardiac action potential, as shown in pre‐clinical stud-
ies using arterially perfused, canine wedge preparations,4 or circus‐
type/spiral wave activity around an anatomical or functional obstacle.
Regardless of the precise underlying mechanism for re‐entry, this
transmural dispersion of repolarization can be quantified electrocar-
diographically by the interval from the peak to the end of the T‐
wave (Tpeak‐Tend interval), (Tpeak‐Tend)/QT ratio and Tpeak‐Tend
dispersion.5,6
However, not all studies have shown an association between
higher Tpeak‐Tend intervals, (Tpeak‐Tend)/QT ratio or Tpeak‐Tend disper-
sion with an arrhythmogenic phenotype in Brugada Syndrome.
Recently, Mugnai and colleagues conducted one of the largest retro-
spective studies to date, including a total of 448 patients with spon-
taneous or drug induced type 1 Brugada pattern.7 They found no
statistically significant difference in all three indices between asymp-
tomatic subjects and patients with syncope and malignant arrhyth-
mias. Morita and colleagues also found in 471 patients no difference
in Tpeak‐Tend intervals between patients with syncope or VT/VF and
those who were asymptomatic.8 These findings contrast with a
meta‐analysis published previously by some members of our group,
which extracted and pooled odds or hazard ratios for the relation-
ship between Tpeak‐Tend and arrhythmic and/or mortality outcomes in
various clinical conditions, including Brugada Syndrome.9 This
demonstrated prolonged Tpeak‐Tend interval was associated with an
increased risk of ventricular arrhythmias and SCD in Brugada
Syndrome.
However, our previous study did not determine the absolute
mean values for Tpeak‐Tend, nor was it possible to include the largest
dataset from Mugnai and colleagues. Moreover, it did not investigate
the utility of other indices such as (Tpeak‐Tend)/QT ratio or Tpeak‐Tend
dispersion. Therefore, we conducted a systematic review with meta‐
analysis into the relationships between Tpeak‐Tend interval, (Tpeak‐
Tend)/QT ratio and Tpeak‐Tend dispersion and arrhythmic and/or mor-
tality endpoints in Brugada Syndrome.
2 | METHODS
2.1 | Search strategy, inclusion and exclusion
criteria
This study was conducted according to the Preferred Reporting
Items for Systematic Reviews and Meta‐Analyses (PRISM) statement.
PubMed and Embase were searched for studies that investigated the
association between Tpeak‐Tend or Tpeak‐Tend /QT with arrhythmic or
mortality endpoints in Brugada syndrome. The following search
terms were used for both databases: [“Tpeak‐Tend” or “Tpeak‐end”
or “Tp‐e” AND Brugada]. The databases were searched until 1 May
2018 without language restrictions. The following inclusion criteria
were used: (a) the study was a case‐control, prospective or
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retrospective cohort study in human subjects with a Brugada pheno-
type, (b) Tpeak‐Tend intervals or (Tpeak‐Tend) /QT ratios were provided;
(c) predefined adverse events (appropriate implantable cardioverter‐
defibrillator therapy [ICD], syncope, ventricular tachycardia/fibrilla-
tion [VT/VF], SCD, cardiovascular death [CVD], major adverse cardiac
events [MACE]) or all‐cause mortality were reported. In cases of
incomplete data from the published studies, the original authors
were contacted, but no replies were received.
The Newcastle‐Ottawa Quality Assessment Scale (NOS) was
used for quality assessment of the included studies.10 The NOS sys-
tem evaluated the categories of study participant selection, results
comparability, and quality of the outcomes. Specifically, the following
characteristics were assessed: (a) representativeness of the exposed
cohort; (b) selection of the non‐exposed cohort; (c) ascertainment of
exposure; (d) demonstration that outcome of interest was not pre-
sent at the start of study; (e) comparability of cohorts based on
study design or analysis; (f) assessment of outcomes; (g) follow‐up
periods that were sufficiently long for outcomes to occur; and (h)
adequacy of follow‐up of cohorts. This scale varied from zero to nine
stars, which indicated that studies were graded as poor quality if the
score was <5, fair if the score was 5‐7, and good if the score was
>8. Studies with a score equal to or higher than six were included.
The details of the NOS quality assessment are shown in Tables S1
and S2.
2.2 | Data extraction and statistical analysis
Data from the different studies were entered in pre‐specified
spreadsheets in Microsoft Excel. All potentially relevant studies were
retrieved as complete manuscripts, which were assessed fully to
determine their compliance with the inclusion criteria. We extracted
the following data from the included studies: (a) publication details:
last name of first author, publication year and locations; (b) study
design; (c) endpoint(s); (d) quality score; and (e) characteristics of the
population including sample size, gender, age and number of sub-
jects. Two reviewers (GT and MG) reviewed each included study
independently. Disagreements were resolved by adjudication with
input from a third reviewer (TL).
Adverse events were defined as ventricular arrhythmias (VT/VF),
SCD, cardiovascular death, MACE or all‐cause mortality. If more than
one mortality endpoint was described, then SCD was preferentially
used for analysis, followed by cardiovascular and all‐cause mortality
in this order. Mean differences between event‐positive and event‐
negative groups, with 95% confidence intervals (CIs) for Tpeak‐Tend
interval, (Tpeak‐Tend)/QT ratio and Tpeak‐Tend dispersion were
extracted and subsequently combined to generate a pooled estimate.
Heterogeneity between studies was quantified using The
Cochran's Q value and the I2 statistic from the standard chi‐square
test, which describes the percentage of the variability in effect esti-
mates resulting from heterogeneity. I2 > 50% was considered to
reflect significant statistical heterogeneity. A fixed effects model was
used if I2 < 50%. The random‐effect model using the inverse vari-
ance heterogeneity method was used when I2 > 50%. To locate the
origin of the heterogeneity, sensitivity analysis by excluding one
study at a time, and subgroup analyses based on different disease
conditions and different endpoints were performed. Funnel plots,
Begg and Mazumdar rank correlation test and Egger's test were used
to detect publication bias.
3 | RESULTS
Figure 1 shows a flow diagram detailing the above search terms with
inclusion and exclusion criteria. A total of 29 and 57 entries were
retrieved from PubMed and Embase, respectively. Nine studies met
the inclusion criteria and were included in our final meta‐analy-
sis.6,7,11-17 In this meta‐analysis, a total of 1740 subjects with Bru-
gada Syndrome were included (mean age 45 years old, 80% male).
The mean follow‐up duration was 68 ± 27 months. Of the entire
cohort, 40% had a spontaneous Type 1 pattern and 19% were posi-
tive for SCN5a mutation. The baseline characteristics of these stud-
ies and of the study populations are shown in Table 1.
3.1 | Tpeak‐Tend
For determining Tend, the tangent method and the return of the volt-
age to baseline method were used. Tpeak‐Tend intervals from different
leads and the maximum of these measurements have been pre-
sented by most studies. Regarding maximum Tpeak‐Tend intervals, the
mean value for the event‐positive group was 98.9 ms (95% CI: 90.5‐
107.2 ms) (Figure 2A) and event‐negative group was 87.7 ms (95%
CI: 80.5‐94.9 ms) (Figure 2B). Five studies reported longer values in
the event‐positive compared to event‐negative groups, whereas four
studies reported no significant difference (Figure 2C). Tpeak‐Tend
intervals were 11.9 ms longer (95% CI: 3.6‐20.2 ms, P = 0.005) in
event‐positive patients than in event‐negative patients. The
Cochran's Q value was greater than the degrees of freedom (56 vs
8), indicating that the true effect size was different between studies.
F IGURE 1 Flow diagram of the study selection process
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I2 took a value of 86%, suggesting the presence of substantial
heterogeneity. A funnel plot plotting standard errors against differ-
ences in means is shown in Figure S1. Begg and Mazumdar rank cor-
relation analysis demonstrated that Kendall's Tau took a value of 0.3
with P = 0.30, which suggests no significant publication bias. Egger's
test demonstrated no significant asymmetry (intercept 2.4, t‐value
1.2; P = 0.25). To identify the source of the heterogeneity, sensitiv-
ity analysis was performed by removing one study at a time, but this
did not significantly influence the mean difference (Figure S2), sug-
gesting that no single study was responsible for the heterogeneity
observed in this meta‐analysis. Subgroup analysis based on the
method of Tend determination was performed. For the tangent
method, the Tpeak‐Tend mean difference was 15.5 ms (95% CI: 3.9‐
27.2 ms; P = 0.009) and I2 remained high at 90%. For full recovery
of voltage to baseline, the mean difference was 6.0 ms (95% CI: 0.7‐
11.4 ms; P = 0.006) and I2 remained high at 76%. Therefore, differ-
ent methods of Tend determination did not introduce significant
heterogeneity to the pooled effect estimate.
3.2 | (Tpeak‐Tend)/QT ratio
Regarding maximum (Tpeak‐Tend)/QT ratio, the mean value for the
event‐positive group was 0.221 (95% CI: 0.208‐0.234) (Figure 3A)
and event‐negative group was 0.210 (95% CI: 0.205‐0.214) (Fig-
ure 3B). Two studies reported higher values in Brugada subjects
with positive events compared to those without such events,
whereas four studies demonstrated no significance between the
groups (Figure 3C). Pooling of the mean values demonstrated signif-
icantly higher (Tpeak‐Tend)/QT ratios in the event‐positive group than
in the event‐negative group (mean difference = 0.019, 95% CI:
0.003‐0.036, P = 0.024). The Cochran's Q value was greater than
the degrees of freedom (19 vs 5), indicating that the true effect
size was different between studies. I 2 took a value of 74%, sug-
gesting significant heterogeneity. A funnel plot plotting standard
errors against differences in means is shown in Figure S3. Begg and
Mazumdar rank correlation analysis demonstrated that Kendall's
Tau took a value of 0.07 with P = 1, which suggested no significant
publication bias. Egger's test demonstrated no significant asymmetry
(intercept 3.5, t‐value 1.1; P = 0.31). To identify the source of the
heterogeneity, sensitivity analysis was performed by removing one
study at a time, but this did not significantly influence the mean
difference (Figure S4), suggesting that no single study was responsi-
ble for the heterogeneity observed in this meta‐analysis. Subgroup
analysis based on the method of Tend determination was performed.
For the tangent method, the mean difference of (Tpeak‐Tend)/QT
ratio was 0.03 (95% CI: 0.01‐0.05; P < 0.05) and I2 was lowered to
55%. For full recovery of voltage to baseline, the mean difference
was only 0.004 (95% CI: −0.03 to 0.03 ms; P = 0.81) and I2
remained high at 74%. Therefore, different method of Tend determi-
nation appeared to contribute partially to the heterogeneity of the
pooled effect estimate. Moreover, statistical significance was
achieved when the tangent method was used, but was lost when
the return to baseline method was used, which may suggest the
former approach may be more sensitive.
3.3 | Tpeak‐Tend dispersion
Regarding maximum Tpeak‐Tend dispersion, the mean value for the
event‐positive group was 40.8 ms (95% CI: 26.9‐54.8 ms) (Figure 4A)
and event‐negative group was 29.7 ms (95% CI: 24.5‐34.8 ms) (Fig-
ure 4B). Regarding Tpeak‐Tend dispersion, two studies reported longer
values in event‐positive group compared to event‐negative groups,
whereas three studies found no significant difference (Figure 4C).
Overall, pooling of the data showed that Tpeak‐Tend dispersion was sig-
nificantly higher in the event‐positive than in the event‐negative
groups (mean difference = 7.8 ms, 95% CI: 2.1 to 13.4 ms, P = 0.007).
The Cochran's Q value was greater than the degrees of freedom (20 vs
4), indicating that the true effect size was different between studies. I2
took a value of 80%, suggesting significant heterogeneity. A funnel
plot plotting standard errors against differences in means is shown in
Figure S5. Begg and Mazumdar rank correlation analysis demonstrated
that Kendall's Tau took a value of −2 with P = 0.62, which suggests no
significant publication bias. Egger's test demonstrated no significant
asymmetry (intercept −5.4, t‐value 0.8; P = 0.48). To identify the
source of the heterogeneity, sensitivity analysis was performed by
removing one study at a time, but this did not significantly influence
the mean difference between event‐positive and event‐negative
groups (Figure S6), suggesting that no single study was responsible for
the heterogeneity observed in this meta‐analysis. Subgroup analysis
based on the method of Tend determination was performed. For the
tangent method, the mean difference of Tpeak‐Tend dispersion was
16.2 ms (95% CI: 7.9‐24.5 ms; P < 0.0001) and I2 was 65%. For full
recovery of voltage to baseline, the mean difference was 0.4 ms (95%
CI: −7.3 to 8.2 ms; P = 0.91) and I2 was reduced to 19%. Therefore,
different method of Tend determination contributed heterogeneity to
the pooled effect estimate. Moreover, statistical significance was
achieved when the tangent method was used, but was lost when the
return to baseline method was used, which may suggest the former
approach may be more sensitive.
3.4 | Comparisons between patients with and
without SCN5A mutations
SCN5A is the commonest ion channel gene that is mutated in Bru-
gada syndrome.2,3 Separate meta‐analyses were conducted to com-
pare the different Tpeak‐Tend parameters between patients with and
without SCN5A mutations. Two of the included studies provided
sufficient information for such analyses.7,14 No significant difference
in Tpeak‐Tend (mean difference = 8.2 ms, 95% CI: −6.7 to 23.2 ms,
P = 0.28; I2 = 59%; Figure S7), Tpeak‐Tend/QT ratio (mean differ-
ence = −0.006 ms, 95% CI: −0.023 to 0.011 ms, P = 0.47; I2 = 24%;
Figure S8) or Tpeak‐Tend dispersion (mean difference = 5.2 ms, 95%
CI: −2.9 to 13.2 ms, P = 0.21; I2 = 31%; Figure S9) was observed
between patients with and without SCN5A mutations.
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4 | DISCUSSION
The main findings of our meta‐analysis, which included 1597 Bru-
gada subjects, are (a) Tpeak‐Tend intervals, (b) (Tpeak‐Tend)/QT ratio and
(c) Tpeak‐Tend dispersion are higher in Brugada subjects with adverse
cardiac events (ventricular tachy‐arrhythmias and SCD) when com-
pared to Brugada subjects free from such events.
The presence of pre‐existing electrophysiological heterogeneities
is important for mediating the normal, unidirectional spread of action
potentials in the heart.18,19 These are attributed to differences in
repolarization times of the different cell types, which are responsible
for generation of the T‐wave on the electrocardiogram (ECG).20,21
However, exacerbation of such differences has been associated with
ventricular tachy‐arrhythmias in different conditions, thereby gener-
ating a pro‐arrhythmic phenotype. These include congenital ion
channelopathies such as long QT syndrome and Brugada syn-
drome22-24 and acquired cardiac diseases such as myocardial infarc-
tion.25,26 These heterogeneities can occur locally or across the
F IGURE 2 Forest plot demonstrating Tpeak‐Tend intervals obtained from event‐positive (A) and event‐negative (B) groups and the mean
difference between both groups (C) in Brugada Syndrome
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myocardial wall,27 potentially causing arrhythmias by inducing unidi-
rectional conduction block and therefore circus‐type or spiral wave
re‐entry.28,29 Moreover, a greater epicardial‐endocardial repolariza-
tion time difference may increase the propensity of phase 2 re‐entry,
which is hypothesized to generate extrasystolic activity in Brugada
syndrome.30 This occurs when sites with an action potential dome
to sites which a dome morphology, leading to direct depolarization
of the downstream sites.31 Once an extrasystole is generated,
together with a favorable re‐entrant substrate, ventricular tachycar-
dia and fibrillation can result.32
A number of electrocardiographic indices have been proposed
for stratification of arrhythmic or mortality risk.33,34 Of these, Yan
and Antzelevitch were the first to propose the use of the difference
between the peak and the end of the T‐wave (the Tpeak‐Tend interval)
as a measure of transmural dispersion of repolarization.20,35-37 Sub-
sequent clinical studies have demonstrated that, confirmed recently
in a systematic review and meta‐analysis from our group,9 that Tpeak‐
Tend prolongation significantly elevated the risk of ventricular tachy‐
arrhythmias and/or SCD in heart failure, ischemic heart disease, Bru-
gada syndrome, hypertension, and the general population. Recently,
Mugnai and colleagues in a total of 448 subjects found no significant
differences Tpeak‐Tend intervals, (Tpeak‐Tend)/QT ratio or Tpeak‐Tend dis-
persion between patients with VT/VF requiring anti‐tachycardia pac-
ing or with sudden death, and those who were asymptomatic.7
Similarly, in a separate population of 471 subjects, Morita and col-
leagues found no significance difference in Tpeak‐Tend intervals
F IGURE 3 Forest plot demonstrating Tpeak‐Tend/QT ratios obtained from event‐positive (A) and event‐negative (B) groups and the mean
difference between both groups (C) in Brugada Syndrome
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between patients with syncope or VT/VF and asymptomatic
patients.16 Publication of these two studies prompted us to conduct
this meta‐analysis, which confirms the value of Tpeak‐Tend interval,
(Tpeak‐Tend)/QT ratio and Tpeak‐Tend dispersion, in distinguishing high‐
risk patients from low‐risk patients.
In the Mugnai study, the largest study to date, the percentage of
patients with adverse events were the lowest at 13%.7 Male gender,
a spontaneous Type 1 Brugada pattern and SCN5a mutation positive
status were significantly associated with ventricular arrhythmias.38
Therefore, the lower percentage of patients with adverse events can
be explained by the lower percentage of Type 1 Brugada patients
(21% vs 28%‐100% in the remaining studies) and lower percentage
male patients (61% vs 72%‐100%) despite similar percentage with
SCN5a positive status (22% vs 13%‐50%). While these differences in
patient characteristics affect the likelihood of adverse events
occurring, they should not explain the lack of difference in Tpeak‐Tend
intervals between event‐positive and event‐negative groups in the
Morita study16 or the Mugnai study. Interestingly, Mugnai and col-
leagues found a non‐statistically significant lower Tpeak‐Tend intervals
in event‐positive groups. Of the remaining six studies, five studies
had reported significantly higher Tpeak‐Tend intervals and one study
reported no difference.15 A recent epidemiological study reported a
U‐shaped relationship between Tpeak‐Tend intervals and increased
mortality.39 Autonomic modulation, which is part of Coumel's triad
for arrhythmogenesis,40 is known to modulate the re‐entrant sub-
strate. Increased activity of the parasympathetic nervous system
may reduce Tpeak‐Tend intervals, which may also be pro‐arrhythmic.41
By contrast, exercise, during which sympathetic activity is increased,
can exacerbate pre‐existing heterogeneities, such as producing con-
duction slowing42 and increasing the dispersion of repolarization.43
F IGURE 4 Forest plot demonstrating Tpeak‐Tend dispersion obtained from event‐positive (A) and event‐negative (B) groups and the mean
difference between both groups (C) in Brugada Syndrome
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In our previous meta‐analysis pooling together studies that
reported odds ratios or hazard ratios, the average cut‐off for Tpeak‐
Tend was 95.8 ms across different clinical conditions.
9 The present
meta‐analysis pooling mean values for event‐positive and ‐negative
groups clearly indicates that the 100 ms cut‐off is too high for Bru-
gada syndrome. Our data would support a lower cut‐off value
between 88 and 99 ms to be used. This cut‐off will also be method‐
dependent for determining Tend in the case of the Tpeak‐Tend inter-
vals. Previously, it was shown that in a cohort of high‐risk Brugada
subjects, only 10 of 16 studies reported a Tpeak‐Tend longer than
100 ms, supporting our notion that this cut‐off value may be too
high.44 Moreover, different studies measured Tpeak‐Tend from differ-
ent leads. Some had measured it from all 12 leads and taken the
mean values while others have done so for V1 to V3 only. While
there is no consensus as to which leads are most appropriate for
measurement, obtaining it from all 12 leads is likely to be less useful
clinically due to the time‐consuming nature. To simplify Tpeak‐Tend
determination, we would thus propose measuring it from the right
precordial leads given BrS is primarily a right ventricular disorder.
While it may appear that the difference in Tpeak‐Tend between
high‐risk and low‐risk Brugada patients was only small, at around
12 ms, it should be emphasized that increased transmural dispersion
of repolarization is only one mechanism by which re‐entrant arrhyth-
mogenesis is generated. Other mechanisms, such as reduced conduc-
tion velocity, increased dispersion of conduction45 or dynamic
substrates such as steep action potential restitution,46 in which nor-
mal Tpeak‐Tend interval, Tpeak‐Tend/QT ratio or Tpeak‐Tend dispersion
may be observed, also contribute to arrhythmogenesis in Brugada
syndrome. Therefore, better risk stratification scores will need to
incorporate a combination of repolarization and conduction indices.
Moreover, some of these dynamic changes may not be detectable
on the ECG and may require additional tests such as non‐invasive
ECG imaging (ECGi),43 or only becomes detectable only under stress-
ful conditions such as exercise.43
4.1 | Limitations
The following limitations of this meta‐analysis should be noted. First,
there is marked heterogeneity between the included studies. The
method of Tpeak‐Tend determination across the studies was split even
between the tangent method and full recovery of the voltage to
baseline. Subgroup analysis based on the method used did not
reduce the heterogeneity observed. Therefore, measurement method
was unlikely to have significantly contributed to the heterogeneity
observed. Moreover, the Letsas 2010 study12 used a different end-
point of inducible VT compared to the remaining studies, but its
exclusion did not significant affect the mean Tpeak‐Tend values for
event‐positive group, event‐negative group, and mean difference
between these groups. Second, retrospective studies may have more
bias than prospective studies. Finally, it should be acknowledged that
there is overlap between event‐postiive and event‐negative groups
irrespective of the method of measuring Tend. This would suggest as
a single measurement, Tpeak‐Tend is unlikely to be useful in its own
right. Indeed, accurate risk stratification will require a composite
scoring system assessing not only dispersion of repolarization, but
that of conduction, clinical symptoms, family history, the type of
Brugada pattern, genetic background, electrical and drug provocation
testing as well as electrophysiological mapping.38,41,45,47-49
5 | CONCLUSIONS
Tpeak‐Tend interval, Tpeak‐Tend/QT ratio and Tpeak‐Tend dispersion were
higher in high‐risk than low‐risk Brugada subjects, and thus offer
incremental value for risk stratification.
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